And I guess I wonder how Arzerra stacks up to the current competition, including PCYC's BTK drug.
In listening to Genmab's Jefferies presentation, the point was made at the very end that Genmab's expectation is that the new oral drugs, like PCYC's BTK inhibitor, will be combined with Arzerra down the road, not replace it. The speaker mentioned the different MoA and the potential for synergy when combining.
Market Data 
Markets 
AI
